“Patent Strategies - Effective Strategies for Extension of Product Lifecycles and Combating Aggressive Generics Markets”, provides in-depth analysis of various patent protection strategies adopted by pharmaceutical companies for maximizing revenues returns from the branded drugs. The report analyzes the effective patent strategies and provides you a multi-strategy approach to defend your products from generics. It gives you a robust idea on successful patent portfolio management. Furthermore, the report analyzes the patent strategies that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
- Understanding of the R&D process and the necessity of patent protection.
- An overview of current patent protection mechanisms employed by pharmaceutical companies.
- Detailed study of pre-patent protection strategies with special emphasis on strategies which help combating generic competition.
- Post-patent expiry strategies like authorized generics and orange book delisting with case studies.
- Inputs for customized patent strategy based on business situation.
- Case studies of successful patent strategies.
Reasons to buy
The report will enhance your decision making capability. It will provide you with:
- Build understanding of the key Patent strategies in place and the trends in the market
- Optimize your R&D pipeline through identification and understanding of the key strategy for your drug.
- Identify the key players best positioned to capitalize on their products through effective management of the lifecycle of their patented products.
- Develop effective business strategies related to Patents through the analytical insight gained from case studies covering different strategies in the market.
- Understand the fit between the patent strategy and your product considering various factors pertaining to the market, product and therapeutic area.
- Ensure success in patent portfolio management through the analysis of key success and failure factors and the use of the framework for measuring performance.
For more please visit
http://www.bharatbook.com/detail.asp?id=167045&rt=Patent-Strategies-Effective-Strategies-for-Extension-of-Product-Lifecycles-and-Combating-Aggressive-Generics-Markets.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Your one-stop-shop for business information
Showing posts with label Drugs. Show all posts
Showing posts with label Drugs. Show all posts
Thursday, December 30, 2010
Tuesday, December 28, 2010
Global Pharmaceutical Market Forecast to 2012
The pharmaceutical market worldwide, after having experienced exponential growth over the past few years, is now witnessing a slump. This decline in global pharma market is largely attributed to the patent expiry of key blockbusters together with saturation in key pharma markets such as the US and Western Europe. Meanwhile, pharma markets in some developing regions like Asia and Latin America have been continuously witnessing robust growth rate in last few years on account of increasing prevalence of diseases, rising healthcare spending and increasing affordability. Overall, these markets enjoy good growth potential in coming few years.
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Global Pharmaceutical Market Forecast to 2012
The pharmaceutical market worldwide, after having experienced exponential growth over the past few years, is now witnessing a slump. This decline in global pharma market is largely attributed to the patent expiry of key blockbusters together with saturation in key pharma markets such as the US and Western Europe. Meanwhile, pharma markets in some developing regions like Asia and Latin America have been continuously witnessing robust growth rate in last few years on account of increasing prevalence of diseases, rising healthcare spending and increasing affordability. Overall, these markets enjoy good growth potential in coming few years.
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Emerging Pharmaceutical Markets Globally
The growth in pharma markets in emerging countries has outpaced the overall growth of the global pharma market. The growth in these markets is being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases, and low-cost factors. In 2008, pharma market in E7 countries (Brazil, Russia, China, India, Turkey, Mexico and Indonesia) was estimated at around US$ 96 Billion, and it is expected that high growth in these markets will help these countries increase their share in global pharma market.
According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the abovementioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.
Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.
The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.
For more please visit
http://www.bharatbook.com/detail.asp?id=73228&rt=Emerging-Pharmaceutical-Markets-Globally.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the abovementioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.
Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.
The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.
For more please visit
http://www.bharatbook.com/detail.asp?id=73228&rt=Emerging-Pharmaceutical-Markets-Globally.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Thursday, December 16, 2010
Healthcare Industry in United States
Health care in the United States is provided by many separate legal entities. Current estimates put US healthcare spending at approximately 15% of GDP, which is the highest in the world. The United States spends the highest percentage of health care costs on pharmaceuticals in the world. The health share of gross domestic product (GDP) is expected to hold steady in 2006 before resuming its historical upward trend, reaching 19.6 percent of GDP by 2016. In the United States, around 85% of citizens have health insurance, either through their employer or purchased individually.
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Healthcare Industry in United States
Health care in the United States is provided by many separate legal entities. Current estimates put US healthcare spending at approximately 15% of GDP, which is the highest in the world. The United States spends the highest percentage of health care costs on pharmaceuticals in the world. The health share of gross domestic product (GDP) is expected to hold steady in 2006 before resuming its historical upward trend, reaching 19.6 percent of GDP by 2016. In the United States, around 85% of citizens have health insurance, either through their employer or purchased individually.
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Wednesday, December 15, 2010
Analyzing the Global Pharmaceutical Industry
The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs. The earliest incidents of recognition of the antiseptic properties of the dyestuffs is around the late 19th century. The invention of penicillin can yet be recognized as a major milestone for the emergent industry which firmly consolidated its R&D efforts in the 1950’s. Further in the 1960’s the patent regulation support gave a further impetus to the industry in new discoveries and relaxed controls on clinical development with the booming spend on healthcare as economies boomed globally.
The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with inter continental treatment demand of patients being serviced from often one or two mega research centers in the continent.
By contribution of size, the pharmaceutical industry is majorly dominant at the US, Europe and Japan. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.
The marketing aggressiveness of US-based companies has placed them at the top of the pile, being followed closely by the European sector. Countries like the UK, France and Denmark each have at least two pharmaceutical companies in their respective ten largest corporate enterprises.
Aruvian's R'search’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up a industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry , competitive activity and the overall market outlook.
The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.
The R&D initiatives practiced by the industry, which are often used to ward off competition as well as developing new alliances, are explained as a major thrust area powering the industry growth in this report. The report presents an invaluable input in the form of analyzing the drug development and lifecycle of a drug from discovery to discontinuation and the kind of R&D costs which are involved in developing that drug. The crucial supportive role of the patent system which energizes innovation in the industry and further efforts on genomics is also elaborated in the report.
The need for corporate social responsibility in the pharma sector which serves as a safeguard for ensuring socially ethical drug development is also provided in this report. The report delves deeper into the pricing questions that always face any global pharmaceutical company wherein the constant tug between reasonability and deriving product costs in conjunction with the objectives of the respective country’s government. The report also throws light on the issues faced by pharmaceutical majors in the developing countries wherein the effects of TRIPS and the pricing of medicines are constantly on the resolution agendas of these companies.
The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report.
The report takes a critical view on the irresponsible drug promotion and advertising practiced by some pharma companies in this majorly ethical business and the issue of protecting IPR’s in the global marketplace.
An interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally along with which the report presents a country wise analysis of the pharmaceutical markets spread globally and their respective industry dynamics which includes a profiling of the major global industry players.
For more please visit
http://www.bharatbook.com/detail.asp?id=161691&rt=Analyzing-the-Global-Pharmaceutical-Industry.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with inter continental treatment demand of patients being serviced from often one or two mega research centers in the continent.
By contribution of size, the pharmaceutical industry is majorly dominant at the US, Europe and Japan. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.
The marketing aggressiveness of US-based companies has placed them at the top of the pile, being followed closely by the European sector. Countries like the UK, France and Denmark each have at least two pharmaceutical companies in their respective ten largest corporate enterprises.
Aruvian's R'search’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up a industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry , competitive activity and the overall market outlook.
The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.
The R&D initiatives practiced by the industry, which are often used to ward off competition as well as developing new alliances, are explained as a major thrust area powering the industry growth in this report. The report presents an invaluable input in the form of analyzing the drug development and lifecycle of a drug from discovery to discontinuation and the kind of R&D costs which are involved in developing that drug. The crucial supportive role of the patent system which energizes innovation in the industry and further efforts on genomics is also elaborated in the report.
The need for corporate social responsibility in the pharma sector which serves as a safeguard for ensuring socially ethical drug development is also provided in this report. The report delves deeper into the pricing questions that always face any global pharmaceutical company wherein the constant tug between reasonability and deriving product costs in conjunction with the objectives of the respective country’s government. The report also throws light on the issues faced by pharmaceutical majors in the developing countries wherein the effects of TRIPS and the pricing of medicines are constantly on the resolution agendas of these companies.
The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report.
The report takes a critical view on the irresponsible drug promotion and advertising practiced by some pharma companies in this majorly ethical business and the issue of protecting IPR’s in the global marketplace.
An interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally along with which the report presents a country wise analysis of the pharmaceutical markets spread globally and their respective industry dynamics which includes a profiling of the major global industry players.
For more please visit
http://www.bharatbook.com/detail.asp?id=161691&rt=Analyzing-the-Global-Pharmaceutical-Industry.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Monday, July 26, 2010
Conference on 6th Annual Drug Delivery Systems
Moving towards effective drug delivery technologies and deal making
1st - 2nd February 2011, BSG Conference Centre, London, UK
Key Speakers:
Dr. Sven Stegemann, Director, Pfizer
Dr. Sophie Van Tomme, Pharmaceutical Scientist, Abbott
Gerrit Hauck, Head PSD R&D Operations, Sanofi -Aventis
Matthew Roe, Senior Director-Business Development and Licensing, Genzyme
Dr. Oliver Steinbach, Department Head, Philips Research Laboratories
Dr. Rajan K. Verma, Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO), Dr Reddy’s Laboratories
Dr. Deirdre McIntosh, Director, McIntosh Scientific Advice Services
Dr. Michel Deleers, CEO, OncoBel
Dr. Andrew Lewis, Operations Director, Critical Pharmaceuticals
Dr. Ben Forbes, Senior Lecturer in Pharmaceutics, King’s College, London
Ketan Pancholi, Lecturer, The Robert Gordon University
Gerry Kamstra Partner, IP & Life Sciences, Bird and Bird
Conference Introduction
Shrinking global capital markets, new healthcare policies, ageing populations, the growth of emerging economies, technological advances and the advent of regenerative and biological medicines are just some of the factors expected to shape the future drug delivery device market. (Source: Cambridge Consultants UK, September 2009)
With increased competition and the growing importance of patience compliance, pharmaceutical companies are working towards developing effective and targeted drug
delivery systems, to transform disease treatments. Now in its 6th year, Drug Delivery Systems Conference showcases the basics and latest developments for inhaled drug, RNAi based therapies and protein and peptide methods. We have put together an unparalleled scientific programme comprising insightful presentations by leading experts from Pfizer, Philips Research, Dr Reddy’s Laboratories and Genzyme. This conference will feature keynote addresses, case studies and interactive discussions
ranging from current and evolving drug delivery technologies to advancement and manufacturing of more efficient formulations.
Attendance at this conference will enable you to:
*
Benefit from thorough updates of recent developments in the drug delivery sector
*
Examine challenges in generic development of drug delivery systems
*
Learn from in-depth case study from Philips about image-guided ultrasound-mediated drug delivery
*
Identify different strategies in managing a drug delivery alliance
*
Know how to overcome the industry challenges for inhaled delivery systems
*
Discuss key regulatory and legal issues
*
Recognise the importance of new biologic delivery technologies
*
Discuss microbubble production technologies and its effect on delivery
*
Create patient centered drug delivery product
*
Network with experts and opinion leaders from pharma, biotech, device and drug delivery industries
Who should attend?
VPs, Directors, Heads, Managers of:
*
Drug Delivery
*
Preformulation /Formulation/Stability
*
Business Development
*
Licensing
*
Technology Assessment
*
Commercial Development
*
Patents
*
Lifecycle Management
*
Strategic Planning and Development
*
Financial Analyst
*
Pharmaceutical and Analytical R&D
*
Pharmaceutical Science
*
Testing
*
Product Development
*
New Product Planning]
*
New Technology Evaluation
*
Marketing
*
Brand Management
*
Product Management
*
Sales
*
Regulatory Affairs
Others:
*
Intellectual Property Attorneys
*
Venture Capitalists
*
Medical Device Companies
*
Analysts/Investment Banks
CROs:
*
Contract Sales Organisations
*
Universities and Government Research
*
Testing and Manufacturing Equipment
*
Packaging Companies
Day 1
6th Annual Drug Delivery Systems
Tuesday 1st February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Imagine a patient would run a formulation lab: Patient centered drug delivery product development
*
From clinical perspectives to therapeutic objectives
*
Identifying patient needs beyond the clinical symptoms
*
Translating scientific excellence in real world therapy enhancement
*
Integrating patient centered drug delivery in healthcare provision
Dr Sven Stegemann
Director, Pfizer
10:20 Realising partnerships with academia, SME’s and Big E in the field of inhalation.
*
The NeoFor project (New formulation and Devices for the inhalation of Macromolecules)
*
Anticancer drug project for lung cancer (Solid lipidic micro particles formulations)
*
Formulations for 2 and 3 molecules
*
Formulations with pegylated mAb’s
*
Other projects in partnering
Dr. Michel Deleers
CEO, OncoBel. Former VP New Pharma Technologies & Academic Liaison, UCB New Medicines
11:00 Morning refreshments
11:20 Inhalation delivery systems: the challenges and opportunities
*
Retention in the lung
*
Absorption from the lung
*
Safety and efficacy
*
Industry challenges & open innovation
Dr. Ben Forbes
Senior Lecturer in Pharmaceutics, King’s College, London
12:00 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
12:40 Networking lunch
13:40 Virtual training course for development of nanoparticulate dosage forms From API to final nanoparticulate drug products
*
Pros and cons of various particle size reduction technologies
*
Practical development tools (Stabilizer screening, Particle size measurements, Solid state analysis, Final dosage form manufacturing, Dissolution aspects, Stability studies)
*
Biopharmaceutical aspects
Dr. Sophie Van Tomme
Pharmaceutical Scientist, Abbott
14:20 Targeted drug delivery using microbubble - An overview
*
Possible approaches of delivering drug using microbubble
*
Microbubble production technologies and its effect on delivery
*
Drug delivery mechanism
*
Advantages and challenges
*
Summary
Ketan Pancholi
Lecturer, The Robert Gordon University
15:00 Afternoon Refreshments
15:20 IMAG(IN)E global-release local - IMAGE guided ultra sound-triggered drug delivery for RNAi-based therapy
*
Medical imaging technologies are becoming an integral part of therapeutic interventions. The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalized medicine. A key success factor for the effective translation of new drug delivery concepts into clinical practice are partnerships with leading academic, medical institutions and industrial partners.
*
Philips’ image-guided ultrasound-mediated drug delivery platform offers researchers a unique approach to investigating the delivery of various therapeutic molecules and capitalizes upon Philips’ existing expertise in medical imaging technologies for diagnosis, therapy planning and minimally-invasive medical procedures. We show advances in temperature sensitive liposomes with incorporated drugs and MRI-imaging labels as well as pressure-sensitive microbubbles with specific ultrasound-imaging and drug release characteristics for the local delivery of nucleic-acid based therapeutics including siRNA.
Dr. Oliver Steinbach
Department Head, Philips Research Laboratories
16:00 Ocular Drug Delivery Systems
*
Challenges and advantages of conventional dosage forms
*
Analysing recent trends in ocular inserts
*
Closing remarks from the chair
16:50 Networking drinks
Day 2
6th Annual Drug Delivery Systems
Wednesday 2nd February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Targeted drug delivery strategies in cancer therapy: The evolution of early concepts
*
Naive concepts in early targeting
*
Toxins as chemotherapeutic agents,
*
Liposomes as Toxin Vectors
*
Physiological barriers to success
*
The emergence of holistic strategies.
Dr. Deirdre McIntosh
Director, McIntosh Scientific Advice Services
10:20 Protein and peptide drug delivery strategies for product lifecycle management
*
Why is new biologic delivery technologies needed?
*
Innovative technologies to deliver therapeutic macromolecules:
- CriticalMix – injectable sustained release of macromolecules
- CriticalSorb – systemic delivery of macromolecules via the intranasal route
Dr. Andrew Lewis
Operations Director, Critical Pharmaceuticals
11:00 Morning refreshments
11:20 Drug synthesis and delivery IP due diligence
*
Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
*
Typical issues around manufacturing process patents
*
Typical issues around drug delivery patents
*
Subsistence of Supplementary Protection Certificates
*
Regulatory data protection and orphan drug
*
Protection in late stage investments
Gerry Kamstra
Partner, IP & Life Sciences, Bird and Bird
12:00 Parenteral sustained release drug delivery systems - Status and perspective
Gerrit Hauck
Head PSD R&D Operations, Sanofi-Aventis
12:40 Networking lunch
13:40 Innovations in generic development of drug delivery systems
*
Drug delivery systems
*
Challenges in generic development of drug delivery systems
- Regulatory
- IP
- Bio requirements
- Technological
*
Case studies
Dr. Rajan K. Verma
Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO)
Dr Reddy’s Laboratories]
14:20 Different strategies in managing a drug delivery alliance
Matthew Roe
Senior Director-Business Development and Licensing, Genzyme
15:00 Afternoon refreshments
15:20 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
16:00 Drug delivery in diabetes
*
Examining various techniques
*
Discussing emerging insulin delivery methods
*
Understanding pricing and reimbursement
16:40 Chair’s closing remarks
16:50 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=111630&rt=Conference-on-6th-Annual-Drug-Delivery-Systems.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
1st - 2nd February 2011, BSG Conference Centre, London, UK
Key Speakers:
Dr. Sven Stegemann, Director, Pfizer
Dr. Sophie Van Tomme, Pharmaceutical Scientist, Abbott
Gerrit Hauck, Head PSD R&D Operations, Sanofi -Aventis
Matthew Roe, Senior Director-Business Development and Licensing, Genzyme
Dr. Oliver Steinbach, Department Head, Philips Research Laboratories
Dr. Rajan K. Verma, Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO), Dr Reddy’s Laboratories
Dr. Deirdre McIntosh, Director, McIntosh Scientific Advice Services
Dr. Michel Deleers, CEO, OncoBel
Dr. Andrew Lewis, Operations Director, Critical Pharmaceuticals
Dr. Ben Forbes, Senior Lecturer in Pharmaceutics, King’s College, London
Ketan Pancholi, Lecturer, The Robert Gordon University
Gerry Kamstra Partner, IP & Life Sciences, Bird and Bird
Conference Introduction
Shrinking global capital markets, new healthcare policies, ageing populations, the growth of emerging economies, technological advances and the advent of regenerative and biological medicines are just some of the factors expected to shape the future drug delivery device market. (Source: Cambridge Consultants UK, September 2009)
With increased competition and the growing importance of patience compliance, pharmaceutical companies are working towards developing effective and targeted drug
delivery systems, to transform disease treatments. Now in its 6th year, Drug Delivery Systems Conference showcases the basics and latest developments for inhaled drug, RNAi based therapies and protein and peptide methods. We have put together an unparalleled scientific programme comprising insightful presentations by leading experts from Pfizer, Philips Research, Dr Reddy’s Laboratories and Genzyme. This conference will feature keynote addresses, case studies and interactive discussions
ranging from current and evolving drug delivery technologies to advancement and manufacturing of more efficient formulations.
Attendance at this conference will enable you to:
*
Benefit from thorough updates of recent developments in the drug delivery sector
*
Examine challenges in generic development of drug delivery systems
*
Learn from in-depth case study from Philips about image-guided ultrasound-mediated drug delivery
*
Identify different strategies in managing a drug delivery alliance
*
Know how to overcome the industry challenges for inhaled delivery systems
*
Discuss key regulatory and legal issues
*
Recognise the importance of new biologic delivery technologies
*
Discuss microbubble production technologies and its effect on delivery
*
Create patient centered drug delivery product
*
Network with experts and opinion leaders from pharma, biotech, device and drug delivery industries
Who should attend?
VPs, Directors, Heads, Managers of:
*
Drug Delivery
*
Preformulation /Formulation/Stability
*
Business Development
*
Licensing
*
Technology Assessment
*
Commercial Development
*
Patents
*
Lifecycle Management
*
Strategic Planning and Development
*
Financial Analyst
*
Pharmaceutical and Analytical R&D
*
Pharmaceutical Science
*
Testing
*
Product Development
*
New Product Planning]
*
New Technology Evaluation
*
Marketing
*
Brand Management
*
Product Management
*
Sales
*
Regulatory Affairs
Others:
*
Intellectual Property Attorneys
*
Venture Capitalists
*
Medical Device Companies
*
Analysts/Investment Banks
CROs:
*
Contract Sales Organisations
*
Universities and Government Research
*
Testing and Manufacturing Equipment
*
Packaging Companies
Day 1
6th Annual Drug Delivery Systems
Tuesday 1st February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Imagine a patient would run a formulation lab: Patient centered drug delivery product development
*
From clinical perspectives to therapeutic objectives
*
Identifying patient needs beyond the clinical symptoms
*
Translating scientific excellence in real world therapy enhancement
*
Integrating patient centered drug delivery in healthcare provision
Dr Sven Stegemann
Director, Pfizer
10:20 Realising partnerships with academia, SME’s and Big E in the field of inhalation.
*
The NeoFor project (New formulation and Devices for the inhalation of Macromolecules)
*
Anticancer drug project for lung cancer (Solid lipidic micro particles formulations)
*
Formulations for 2 and 3 molecules
*
Formulations with pegylated mAb’s
*
Other projects in partnering
Dr. Michel Deleers
CEO, OncoBel. Former VP New Pharma Technologies & Academic Liaison, UCB New Medicines
11:00 Morning refreshments
11:20 Inhalation delivery systems: the challenges and opportunities
*
Retention in the lung
*
Absorption from the lung
*
Safety and efficacy
*
Industry challenges & open innovation
Dr. Ben Forbes
Senior Lecturer in Pharmaceutics, King’s College, London
12:00 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
12:40 Networking lunch
13:40 Virtual training course for development of nanoparticulate dosage forms From API to final nanoparticulate drug products
*
Pros and cons of various particle size reduction technologies
*
Practical development tools (Stabilizer screening, Particle size measurements, Solid state analysis, Final dosage form manufacturing, Dissolution aspects, Stability studies)
*
Biopharmaceutical aspects
Dr. Sophie Van Tomme
Pharmaceutical Scientist, Abbott
14:20 Targeted drug delivery using microbubble - An overview
*
Possible approaches of delivering drug using microbubble
*
Microbubble production technologies and its effect on delivery
*
Drug delivery mechanism
*
Advantages and challenges
*
Summary
Ketan Pancholi
Lecturer, The Robert Gordon University
15:00 Afternoon Refreshments
15:20 IMAG(IN)E global-release local - IMAGE guided ultra sound-triggered drug delivery for RNAi-based therapy
*
Medical imaging technologies are becoming an integral part of therapeutic interventions. The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalized medicine. A key success factor for the effective translation of new drug delivery concepts into clinical practice are partnerships with leading academic, medical institutions and industrial partners.
*
Philips’ image-guided ultrasound-mediated drug delivery platform offers researchers a unique approach to investigating the delivery of various therapeutic molecules and capitalizes upon Philips’ existing expertise in medical imaging technologies for diagnosis, therapy planning and minimally-invasive medical procedures. We show advances in temperature sensitive liposomes with incorporated drugs and MRI-imaging labels as well as pressure-sensitive microbubbles with specific ultrasound-imaging and drug release characteristics for the local delivery of nucleic-acid based therapeutics including siRNA.
Dr. Oliver Steinbach
Department Head, Philips Research Laboratories
16:00 Ocular Drug Delivery Systems
*
Challenges and advantages of conventional dosage forms
*
Analysing recent trends in ocular inserts
*
Closing remarks from the chair
16:50 Networking drinks
Day 2
6th Annual Drug Delivery Systems
Wednesday 2nd February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Targeted drug delivery strategies in cancer therapy: The evolution of early concepts
*
Naive concepts in early targeting
*
Toxins as chemotherapeutic agents,
*
Liposomes as Toxin Vectors
*
Physiological barriers to success
*
The emergence of holistic strategies.
Dr. Deirdre McIntosh
Director, McIntosh Scientific Advice Services
10:20 Protein and peptide drug delivery strategies for product lifecycle management
*
Why is new biologic delivery technologies needed?
*
Innovative technologies to deliver therapeutic macromolecules:
- CriticalMix – injectable sustained release of macromolecules
- CriticalSorb – systemic delivery of macromolecules via the intranasal route
Dr. Andrew Lewis
Operations Director, Critical Pharmaceuticals
11:00 Morning refreshments
11:20 Drug synthesis and delivery IP due diligence
*
Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
*
Typical issues around manufacturing process patents
*
Typical issues around drug delivery patents
*
Subsistence of Supplementary Protection Certificates
*
Regulatory data protection and orphan drug
*
Protection in late stage investments
Gerry Kamstra
Partner, IP & Life Sciences, Bird and Bird
12:00 Parenteral sustained release drug delivery systems - Status and perspective
Gerrit Hauck
Head PSD R&D Operations, Sanofi-Aventis
12:40 Networking lunch
13:40 Innovations in generic development of drug delivery systems
*
Drug delivery systems
*
Challenges in generic development of drug delivery systems
- Regulatory
- IP
- Bio requirements
- Technological
*
Case studies
Dr. Rajan K. Verma
Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO)
Dr Reddy’s Laboratories]
14:20 Different strategies in managing a drug delivery alliance
Matthew Roe
Senior Director-Business Development and Licensing, Genzyme
15:00 Afternoon refreshments
15:20 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
16:00 Drug delivery in diabetes
*
Examining various techniques
*
Discussing emerging insulin delivery methods
*
Understanding pricing and reimbursement
16:40 Chair’s closing remarks
16:50 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=111630&rt=Conference-on-6th-Annual-Drug-Delivery-Systems.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Sunday, July 25, 2010
Conference on Phase I Clinical Trials Summit
Conference on Phase I Clinical Trials Summit
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on 7th Annual Pain Management
Conference on 7th Annual Pain Management
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Cell Based Assays
Key Speakers
• Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer
• Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
• Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories
• Dr. Stefan O. Mueller, Global Head, Early, Genetic and Molecular Toxicology, Merck Serono
• Professor Sir Ian Wilmut, Director, MRC Centre for Regenerative Medicine, University of Edinburgh
• Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca
• Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca
• Dr. Nick Thomas, Principal Scientist, GE Healthcare
• Dr. Rochdi Bouhelal, Senior Investigator, Novartis
• Dr. Daniella Steel, Senior Principal Scientist, Cellartis
• Dr. Julian Burke, Chief Scientific Officer, Genetix
• Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London
• Dr. Jurgen Moll, Director, Department of Cell Biology & Oncology, Nerviano Medical Sciences
• Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
Despite spiralling R&D costs, 90% of lead candidates identified by current in vitro systems fail to become drugs. Setbacks including poor efficacy and unanticipated side effects remain significant challenges, frequently undetected in animal and pre-clinical testing.
New advances in microarray, label-free and stem cell platforms are facilitating faster screening using human cells and dramatically improving next generation models.
This 3-day event, comprising pre-conference workshop and two-day meeting, provides practical insights into the latest developments in this exciting field. With an international faculty of leading experts, accelerate your product launches with insights from key decision makers.
By attending Visiongain's Cell-Based assays conference, you will obtain distilled insights from outstanding speakers, in key areas including:
• Whole-cell screening for GPCR ligands
• Direct small-molecule kinase activation
• Advances and challenges in label-free technologies
• Induced pluripotent and hESCs for drug discovery
• Embryonic stem cell-derived hepatocytes and adult liver cells for CYP450 toxicity evaluation
• Accelerated high-content screening with human cardiac cells
• Neural progenitor cells for HT/uHT testing
• Three-dimensional primary cell cultures for drug development
• Cell migration and uptake assays
• Primary and three-dimensional culture methods for pharmacological profiling
Who should attend?
Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Officers, Directors, Principal Scientists, Franchise Heads and Investigators in:
• Bioanalytical Development
• High-Throughput/High-Content Screening Operations
• Compound Profiling
• Drug Discovery/Validation
• Drug Delivery
• Lead Generation
• In Vitro Sciences
• ADMET
• Pre-clinical Development
• Medicinal Chemistry
• Toxicology
• Stem Cell Technologies & Platforms
• Pharmacovigilance and Safety Testing
• Chemistry and Bioapplications
• GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Pharmacokinetics/Pharmacodynamics
• Global Research and Development
• Business Development
• Investment and Venture Capital
Day 1
Day One, Monday 20th September 2010
09:00 Registration and refreshments
09:30 Opening address from the Chair
Dr. Rochdi Bouhelal
Senior Investigator
Novartis
09:40 Novel trends in high-throughput screening
• The integrated approach to quantity, quality and cost efficiency
• Single cell analysis vs. bulk cell assays
• Miniaturization towards future screening platforms
Professor Helene Andersson Svahn
Research Leader, Department of Nanobiotechnology, Royal Institute of Technology
Managing Director, PicoVitro
10:20 High-performance cell-based assays for flow cytometry and microplate instrument platforms
• No-wash live cell assay of GPCR activation and mitochondrial depolarization
• Lysosomal degradation response system (DRS) cytotoxicity assay
• Functional detection of three different multidrug resistant phenotypes
Dr. Wayne F. Patton
Chief Scientific Officer
Enzo Life Sciences
10:40 Emerging GPCR assay technologies for drug discovery
• Functional assays for GPCR drug discovery and uHTS
• GPCR functional assays and assays to identify biased ligands
• Label-free and other assay technologies for GPCRs spanning from recombinant to physiologically relevant cell systems
Dr. Priya Kunapuli
Director, In Vitro Sciences
External Discovery and Pre-Clinical Sciences
Merck Research Laboratories
11:20 Morning refreshments
11:40 Whole-cell label-free screening for GPCR ligands
• Direct comparison of impedance-based (CellKey) and optical-based instruments (BIND and Epic) for Gi, Gq, and Gs-coupled receptors
• Detecting and distinguishing activation of multiple G-proteins and thus functional selectivity
• An expanding niche for label-free approaches in GPCR screening
Dr. Matthew Peters
Principal Scientist, Lead Generation
AstraZeneca
12:20 Use of xCELLigence technology for uncovering novel functional outputs regulated by the cAMP signalling pathway
• xCELLigence can monitor changes in barrier function in endothelial cells
• xCELLigence as a tool to monitor the onset of hypertrophy in neonatal cardiac myocyte cultures
• Inhibition of cancer cell growth by modulation of the cAMP signalling pathway
Dr. George S. Baillie,
Lecturer, Neuroscience and Molecular Pharmacology
University of Glasgow
12:40 Challenges in kinase-inhibitor screening
• Bottlenecks in target identification
• Crowded chemical space
• Kinase inhibitor toxicities
• Emerging resistance phenomena
• Selectivity issues
Dr. Jurgen Moll
Director, Department of Cell Biology & Oncology
Nerviano Medical Sciences
13:20 Networking lunch
14:20 Development of a label-free imager for monitoring stem cell chemotaxis, invasion, and differentiation
• BIND® - a versatile, label-free system for high-throughput cell-based assays
• High-throughput, low cell number chemotaxis and invasion assays – without transwells
• BIND Imager® enables high-throughput, label-free assays for stem cell differentiation
Dr. Steven Shamah
Director of Cell Biology
SRU Biosystems
15:00 Accelerated high-content screening
• Cell-cycle specific assays
• Apoptosis and cell death
Dr. Julian Burke
Chief Scientific Officer
Genetix
15:40 Afternoon refreshments
16:00 High-throughput 3D cell cultures for drug discovery and human toxicology
• Cell-based microarray platforms
• Adoption of multiple cell-based assays into high-throughput format
• Metabolism-based toxicity screening for pharmaceuticals and cosmetics
Dr. Jonathan Dordick
Director, Center for Biotechnology & Interdisciplinary Studies Rensselaer Polytechnic Institute
Co-Founder, Solidus Biosciences
16:40 Panel discussion: A network view of disease and compound screening
Topics discussed will include: utilising diverse screening methodologies to maximise lead optimisation, and moving towards physiologically relevant disease models for more accurate lead identification. The impact of chemical biology to identify integrated networks in disease and prospects for HT screens on personalized drug discovery will also be discussed. Please email any questions you have for the panel to: john.shah@visiongainglobal.com.
Chair: Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics
Pfizer
Panelists: Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories
Dr. Jonathan Dordick, Director, Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute, Co-Founder, Solidus Biosciences
Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
Dr. Rune Linding, Team Leader, Cellular and Molecular Logic Team, Institute of Cancer Research
17:20 Closing remarks from the chair
17:30 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 2
Day Two, Tuesday 21st September 2010
09:00 Registration and refreshments
09:30 Opening address from the Chair
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology
Merck Serono
09:40 Screening tools for toxicity and drug discovery
• Overview on screening tools for discovery toxicology
• Use of omics to explain and predict toxicities
• Hepatocytes for ADMET
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology
Merck Serono
10:20 Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties
• Metabolic stability
• Drug-drug interactions and toxicity evaluation
• Transporter studies
Dr. Albert Li
President and Chief Executive Officer
Advanced Pharmaceutical Sciences
11:00 Morning refreshments
11:20 Functional hepatocytes from human induced pluripotent stem cells as liver disease models
• iPSC hepatocytes as alternatives to primary human hepatocytes
• Generation of a hepatocyte library
• Prospects for the identification and testing of new medicines and disease modelling
Professor Sir Ian Wilmut
Director, MRC Centre for Regenerative Medicine
University of Edinburgh
12:00 Human embryonic stem cells in drug testing and discovery
• hESCs as a model for embryotoxicity screening
• Disease-specific hESCs in biomarker and drug discovery
• What is preventing hESC utilisation at the rapid pace that befits their enormous potential?
Dr. Dusko Ilic
Senior Lecturer in Stem Cell Science
King’s College London
12:40 Networking lunch
13:40 Cell models and assays for investigative toxicology
• hESC derived cell models for hepatotoxicity and cardiotoxicity
• High content analysis for cellular toxicity
• Electrophysiology for cardiotoxicity
Dr. Nick Thomas
Principal Scientist
GE Healthcare
14:20 Use of human pluripotent stem cell derived cardiomyocytes for drug discovery and development
• Derivation and characteristics of cardiomyocytes from hESC
• Utility of hESC-derived cardiomyocytes for cardiotoxicity testing
• Validation and bench-marking to existing models
Dr. Daniella Steel
Senior Principal Scientist
Cellartis
15:00 Afternoon refreshments
15:20 Panel discussion: Stem cells in drug development- where are we and what are prospects for the future?
Topics discussed will include: advantages and disadvantages over human primary cells, efficacy in pre-clinical testing, and current safety challenges. Please email any questions you have for the panel to: john.shah@visiongainglobal.com.
Panelists: Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London
Dr. Nick Thomas, Principal Scientist, GE Healthcare
Dr. Daniella Steel, Senior Principal Scientist , Cellartis
16:00 A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery
• Limitations of current HTS compound screening
• An organotypic EC-vSMC co-culture assay system compatible with high-throughput/high-content image screening
• Quantitative evaluation of anti-angiogenic inhibitors
Dr. David Micklem
Chief Scientific Officer
BerGenBio
16:40 Primary brain cells for drug screening: the brain chip platform
• Use of primary neurons for high content screening
• Dissecting cell-cell signaling in neuroinflammation
Dr. Fabio Bianco
Chief Executive Officer
Neuro-Zone
17:20 Chair’s closing remarks
17:30 End of conference
Workshop
Post-conference Workshop, Wednesday 22nd September 2010
Label-Free Cellular Assays: The Relevant Future of Drug Discovery
Led by: Mr. Ryan McGuinness, Principal, Ryan McGuinness Consultants
Panelists: Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
Dr. Rochdi Bouhelal, Senior Investigator, Novartis
Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca
Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca
Timings: 09:30 - 10:00 Coffee & Registration
10:00 - 15:00 Workshop
Timing includes lunch and refreshment breaks
The purpose of the workshop is to allow you to engage in knowledge sharing with your peers in a smaller, less formal environment than the main conference. As such, the audience size will typically be no more than 20 participants in order to enable maximum interaction between the workshop leader and the delegates. The format is also more interactive, with less emphasis on ‘lecture-style’ presentations and more emphasis on group discussions, exercises and Q&A sessions.
A review of Label-free cell based assays - what they are, how they work and where they fit.
Today a majority of compound screening campaigns performed by the Biopharmaceutical industry rely on cell-based assays for one particular reason: cell-based assays enable functional measures of target activation in a more relevant and informative setting when compared to biochemical assays. Label-free cellular assays are driving this paradigm forward with their exquisite sensitivity, robustness, ease of use and flexibility. These assays are now performed routinely throughout early drug discovery from target identification and validation to primary screening, lead identification and lead optimization and into safety and toxicology. Through their sensitivity to endogenous levels of receptor targets in cell types closely aligned to the disease processes under study, these technologies provide highly accurate models of complex biological states in formats compatible with industrialized drug screening.
During this workshop we will review the leading, commercially available label-free cellular assay platforms and discuss their applications, advantages and disadvantages. We will have a full discussion of the underlying technology of each platform and compare their abilities to advance various stages of the drug discovery process. We will also explore where label-free technologies fit in the process and how they can be utilized to promote better decision making about which lead candidates to advance. The future of these exciting new technologies is in their ability to create opportunities for researchers to put a higher degree of cell biology into their drug discovery in ways that until now were unattainable.
Lessons Learned
• In-depth understanding of the leading label-free cellular assay technologies currently on the market.
• Discussion of label-free’s placement in the drug discovery process.
• Advantages and disadvantages of adopting label-free cell based assay technologies.
• Case studies illustrating the utility of label-free assays.
• Discussion of the future directions of these technologies.
About your workshop leader
Ryan McGuinness was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and spent time as a private research consultant. His research background encompasses broad areas of molecular cell biology including gene therapy, cellular therapeutics, receptor-mediated signal transduction and functional pharmacology. Ryan has also held customer-facing positions related to the introduction of novel technologies to the Biopharmaceutical industry. He has most recently contributed his expertise to the development and commercialization of the CellKey System family of label-free products at MDS Analytical Technologies. Working at the forefront of label-free cell based assays Ryan has developed numerous applications, published multiple scientific communications and lead collaborations world wide with well-known drug discovery teams from companies like Merck, Amgen, J & J, Novartis and AstraZeneca.
For more information visit
http://www.bharatbook.com/detail.asp?id=129855&rt=Conference-on-Cell-Based-Assays-Conference-and-Workshop.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
• Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer
• Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
• Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories
• Dr. Stefan O. Mueller, Global Head, Early, Genetic and Molecular Toxicology, Merck Serono
• Professor Sir Ian Wilmut, Director, MRC Centre for Regenerative Medicine, University of Edinburgh
• Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca
• Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca
• Dr. Nick Thomas, Principal Scientist, GE Healthcare
• Dr. Rochdi Bouhelal, Senior Investigator, Novartis
• Dr. Daniella Steel, Senior Principal Scientist, Cellartis
• Dr. Julian Burke, Chief Scientific Officer, Genetix
• Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London
• Dr. Jurgen Moll, Director, Department of Cell Biology & Oncology, Nerviano Medical Sciences
• Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
Despite spiralling R&D costs, 90% of lead candidates identified by current in vitro systems fail to become drugs. Setbacks including poor efficacy and unanticipated side effects remain significant challenges, frequently undetected in animal and pre-clinical testing.
New advances in microarray, label-free and stem cell platforms are facilitating faster screening using human cells and dramatically improving next generation models.
This 3-day event, comprising pre-conference workshop and two-day meeting, provides practical insights into the latest developments in this exciting field. With an international faculty of leading experts, accelerate your product launches with insights from key decision makers.
By attending Visiongain's Cell-Based assays conference, you will obtain distilled insights from outstanding speakers, in key areas including:
• Whole-cell screening for GPCR ligands
• Direct small-molecule kinase activation
• Advances and challenges in label-free technologies
• Induced pluripotent and hESCs for drug discovery
• Embryonic stem cell-derived hepatocytes and adult liver cells for CYP450 toxicity evaluation
• Accelerated high-content screening with human cardiac cells
• Neural progenitor cells for HT/uHT testing
• Three-dimensional primary cell cultures for drug development
• Cell migration and uptake assays
• Primary and three-dimensional culture methods for pharmacological profiling
Who should attend?
Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Officers, Directors, Principal Scientists, Franchise Heads and Investigators in:
• Bioanalytical Development
• High-Throughput/High-Content Screening Operations
• Compound Profiling
• Drug Discovery/Validation
• Drug Delivery
• Lead Generation
• In Vitro Sciences
• ADMET
• Pre-clinical Development
• Medicinal Chemistry
• Toxicology
• Stem Cell Technologies & Platforms
• Pharmacovigilance and Safety Testing
• Chemistry and Bioapplications
• GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Pharmacokinetics/Pharmacodynamics
• Global Research and Development
• Business Development
• Investment and Venture Capital
Day 1
Day One, Monday 20th September 2010
09:00 Registration and refreshments
09:30 Opening address from the Chair
Dr. Rochdi Bouhelal
Senior Investigator
Novartis
09:40 Novel trends in high-throughput screening
• The integrated approach to quantity, quality and cost efficiency
• Single cell analysis vs. bulk cell assays
• Miniaturization towards future screening platforms
Professor Helene Andersson Svahn
Research Leader, Department of Nanobiotechnology, Royal Institute of Technology
Managing Director, PicoVitro
10:20 High-performance cell-based assays for flow cytometry and microplate instrument platforms
• No-wash live cell assay of GPCR activation and mitochondrial depolarization
• Lysosomal degradation response system (DRS) cytotoxicity assay
• Functional detection of three different multidrug resistant phenotypes
Dr. Wayne F. Patton
Chief Scientific Officer
Enzo Life Sciences
10:40 Emerging GPCR assay technologies for drug discovery
• Functional assays for GPCR drug discovery and uHTS
• GPCR functional assays and assays to identify biased ligands
• Label-free and other assay technologies for GPCRs spanning from recombinant to physiologically relevant cell systems
Dr. Priya Kunapuli
Director, In Vitro Sciences
External Discovery and Pre-Clinical Sciences
Merck Research Laboratories
11:20 Morning refreshments
11:40 Whole-cell label-free screening for GPCR ligands
• Direct comparison of impedance-based (CellKey) and optical-based instruments (BIND and Epic) for Gi, Gq, and Gs-coupled receptors
• Detecting and distinguishing activation of multiple G-proteins and thus functional selectivity
• An expanding niche for label-free approaches in GPCR screening
Dr. Matthew Peters
Principal Scientist, Lead Generation
AstraZeneca
12:20 Use of xCELLigence technology for uncovering novel functional outputs regulated by the cAMP signalling pathway
• xCELLigence can monitor changes in barrier function in endothelial cells
• xCELLigence as a tool to monitor the onset of hypertrophy in neonatal cardiac myocyte cultures
• Inhibition of cancer cell growth by modulation of the cAMP signalling pathway
Dr. George S. Baillie,
Lecturer, Neuroscience and Molecular Pharmacology
University of Glasgow
12:40 Challenges in kinase-inhibitor screening
• Bottlenecks in target identification
• Crowded chemical space
• Kinase inhibitor toxicities
• Emerging resistance phenomena
• Selectivity issues
Dr. Jurgen Moll
Director, Department of Cell Biology & Oncology
Nerviano Medical Sciences
13:20 Networking lunch
14:20 Development of a label-free imager for monitoring stem cell chemotaxis, invasion, and differentiation
• BIND® - a versatile, label-free system for high-throughput cell-based assays
• High-throughput, low cell number chemotaxis and invasion assays – without transwells
• BIND Imager® enables high-throughput, label-free assays for stem cell differentiation
Dr. Steven Shamah
Director of Cell Biology
SRU Biosystems
15:00 Accelerated high-content screening
• Cell-cycle specific assays
• Apoptosis and cell death
Dr. Julian Burke
Chief Scientific Officer
Genetix
15:40 Afternoon refreshments
16:00 High-throughput 3D cell cultures for drug discovery and human toxicology
• Cell-based microarray platforms
• Adoption of multiple cell-based assays into high-throughput format
• Metabolism-based toxicity screening for pharmaceuticals and cosmetics
Dr. Jonathan Dordick
Director, Center for Biotechnology & Interdisciplinary Studies Rensselaer Polytechnic Institute
Co-Founder, Solidus Biosciences
16:40 Panel discussion: A network view of disease and compound screening
Topics discussed will include: utilising diverse screening methodologies to maximise lead optimisation, and moving towards physiologically relevant disease models for more accurate lead identification. The impact of chemical biology to identify integrated networks in disease and prospects for HT screens on personalized drug discovery will also be discussed. Please email any questions you have for the panel to: john.shah@visiongainglobal.com.
Chair: Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics
Pfizer
Panelists: Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories
Dr. Jonathan Dordick, Director, Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute, Co-Founder, Solidus Biosciences
Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
Dr. Rune Linding, Team Leader, Cellular and Molecular Logic Team, Institute of Cancer Research
17:20 Closing remarks from the chair
17:30 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 2
Day Two, Tuesday 21st September 2010
09:00 Registration and refreshments
09:30 Opening address from the Chair
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology
Merck Serono
09:40 Screening tools for toxicity and drug discovery
• Overview on screening tools for discovery toxicology
• Use of omics to explain and predict toxicities
• Hepatocytes for ADMET
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology
Merck Serono
10:20 Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties
• Metabolic stability
• Drug-drug interactions and toxicity evaluation
• Transporter studies
Dr. Albert Li
President and Chief Executive Officer
Advanced Pharmaceutical Sciences
11:00 Morning refreshments
11:20 Functional hepatocytes from human induced pluripotent stem cells as liver disease models
• iPSC hepatocytes as alternatives to primary human hepatocytes
• Generation of a hepatocyte library
• Prospects for the identification and testing of new medicines and disease modelling
Professor Sir Ian Wilmut
Director, MRC Centre for Regenerative Medicine
University of Edinburgh
12:00 Human embryonic stem cells in drug testing and discovery
• hESCs as a model for embryotoxicity screening
• Disease-specific hESCs in biomarker and drug discovery
• What is preventing hESC utilisation at the rapid pace that befits their enormous potential?
Dr. Dusko Ilic
Senior Lecturer in Stem Cell Science
King’s College London
12:40 Networking lunch
13:40 Cell models and assays for investigative toxicology
• hESC derived cell models for hepatotoxicity and cardiotoxicity
• High content analysis for cellular toxicity
• Electrophysiology for cardiotoxicity
Dr. Nick Thomas
Principal Scientist
GE Healthcare
14:20 Use of human pluripotent stem cell derived cardiomyocytes for drug discovery and development
• Derivation and characteristics of cardiomyocytes from hESC
• Utility of hESC-derived cardiomyocytes for cardiotoxicity testing
• Validation and bench-marking to existing models
Dr. Daniella Steel
Senior Principal Scientist
Cellartis
15:00 Afternoon refreshments
15:20 Panel discussion: Stem cells in drug development- where are we and what are prospects for the future?
Topics discussed will include: advantages and disadvantages over human primary cells, efficacy in pre-clinical testing, and current safety challenges. Please email any questions you have for the panel to: john.shah@visiongainglobal.com.
Panelists: Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London
Dr. Nick Thomas, Principal Scientist, GE Healthcare
Dr. Daniella Steel, Senior Principal Scientist , Cellartis
16:00 A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery
• Limitations of current HTS compound screening
• An organotypic EC-vSMC co-culture assay system compatible with high-throughput/high-content image screening
• Quantitative evaluation of anti-angiogenic inhibitors
Dr. David Micklem
Chief Scientific Officer
BerGenBio
16:40 Primary brain cells for drug screening: the brain chip platform
• Use of primary neurons for high content screening
• Dissecting cell-cell signaling in neuroinflammation
Dr. Fabio Bianco
Chief Executive Officer
Neuro-Zone
17:20 Chair’s closing remarks
17:30 End of conference
Workshop
Post-conference Workshop, Wednesday 22nd September 2010
Label-Free Cellular Assays: The Relevant Future of Drug Discovery
Led by: Mr. Ryan McGuinness, Principal, Ryan McGuinness Consultants
Panelists: Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
Dr. Rochdi Bouhelal, Senior Investigator, Novartis
Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca
Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca
Timings: 09:30 - 10:00 Coffee & Registration
10:00 - 15:00 Workshop
Timing includes lunch and refreshment breaks
The purpose of the workshop is to allow you to engage in knowledge sharing with your peers in a smaller, less formal environment than the main conference. As such, the audience size will typically be no more than 20 participants in order to enable maximum interaction between the workshop leader and the delegates. The format is also more interactive, with less emphasis on ‘lecture-style’ presentations and more emphasis on group discussions, exercises and Q&A sessions.
A review of Label-free cell based assays - what they are, how they work and where they fit.
Today a majority of compound screening campaigns performed by the Biopharmaceutical industry rely on cell-based assays for one particular reason: cell-based assays enable functional measures of target activation in a more relevant and informative setting when compared to biochemical assays. Label-free cellular assays are driving this paradigm forward with their exquisite sensitivity, robustness, ease of use and flexibility. These assays are now performed routinely throughout early drug discovery from target identification and validation to primary screening, lead identification and lead optimization and into safety and toxicology. Through their sensitivity to endogenous levels of receptor targets in cell types closely aligned to the disease processes under study, these technologies provide highly accurate models of complex biological states in formats compatible with industrialized drug screening.
During this workshop we will review the leading, commercially available label-free cellular assay platforms and discuss their applications, advantages and disadvantages. We will have a full discussion of the underlying technology of each platform and compare their abilities to advance various stages of the drug discovery process. We will also explore where label-free technologies fit in the process and how they can be utilized to promote better decision making about which lead candidates to advance. The future of these exciting new technologies is in their ability to create opportunities for researchers to put a higher degree of cell biology into their drug discovery in ways that until now were unattainable.
Lessons Learned
• In-depth understanding of the leading label-free cellular assay technologies currently on the market.
• Discussion of label-free’s placement in the drug discovery process.
• Advantages and disadvantages of adopting label-free cell based assay technologies.
• Case studies illustrating the utility of label-free assays.
• Discussion of the future directions of these technologies.
About your workshop leader
Ryan McGuinness was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and spent time as a private research consultant. His research background encompasses broad areas of molecular cell biology including gene therapy, cellular therapeutics, receptor-mediated signal transduction and functional pharmacology. Ryan has also held customer-facing positions related to the introduction of novel technologies to the Biopharmaceutical industry. He has most recently contributed his expertise to the development and commercialization of the CellKey System family of label-free products at MDS Analytical Technologies. Working at the forefront of label-free cell based assays Ryan has developed numerous applications, published multiple scientific communications and lead collaborations world wide with well-known drug discovery teams from companies like Merck, Amgen, J & J, Novartis and AstraZeneca.
For more information visit
http://www.bharatbook.com/detail.asp?id=129855&rt=Conference-on-Cell-Based-Assays-Conference-and-Workshop.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on CNS Clinical Trials
Conference on CNS Clinical Trials
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on 4th Annual Pharmaceutical PLM
Conference on 4th Annual Pharmaceutical PLM
14th - 15th September 2010, BSG Conference Centre, London, UK
Key Speakers
• Jonathan Deutsch, Director Pharma Development Safety, Licensing and Early Development, Hoffmann-La Roche
• Maciej Gil, Medical & Regulatory Director & CIS, Eli Lilly Russia
• Mario Maio, Head of Formulation & Process Development , Merck Serono
• James Down, Vice President, Product Lifecycle Management, Beckton Dickinson
• Ralph C. Schimmer, Global Head Drug Safety Sciences - Metabolism and Cardiovascular, Hoffmann-La Roche
• Vishal K. Gupta, Director Pharmaceutical R&D, Covidien
• Alok Aggarwal, Co-Founder and Chairman, Evalueserve
• Alexandra C. Gruber, Director Business Development & Marketing, BIOCRATES Life Sciences
• Mike Rea, Chief Executive Officer, IdeaPharma
• Peter G Nielsen, Executive Vice President of Pharmaceutical Development and Chemistry Manufacturing & Control, Lifecycle Pharma
• Nigel Stoate, Partner, Taylor Wessing
• Paul FitzGerald, Owner, Syntropy Medica
Pharmaceutical and biopharmaceutical companies are under severe pressure to improve product pipelines, accelerate time to market, and improve margins on existing products, while maintaining strict adherence to quality principles and regulatory requirements. It is imperative that pharmaceutical and biotech companies address these business challenges to stay competitive, increase revenue, enhance profit, and reduce the risk of noncompliance.
4th Annual Pharmaceutical PLM Conference will feature keynote addresses, presentations, case studies and interactive discussions from development to commercialisation, quality control, supplier issues, regulation and inspection. Please be sure to register your participation amongst the industry's elite for this intensive two-day of learning, networking and exploiting business opportunities.
By attending this conference, you will:
• Hear from R&D, design, engineering and technical professionals and executives
• Recognise the potential benefit of PLM in drug development process
• Learn how to achieve target quality profiles and comply with regulatory requirements
• Find out how partnerships with technology vendors can maximise value through an efficient PLM implementation
• Eliminate inconsistent branding, improve brand communication and enable brand growth
• Gain knowledge of how to manage PLM in a patent environment
Who should attend:
Vice/Presidents, Directors, Heads of:-
• Lifecycle Management
• Portfolio Management Research & Development
• Strategic Planning Partnering
• Licensing & Alliance
• Process Chemists, Pre-Formulation
• Formulation Clinical Scientists
• Clinical Investigators
• Brand Management
• Patent
• Regulatory Affairs
Target audience - industry
Pharmaceutical companies, biopharmaceutical
companies, software vendors, PLM vendors, Analysts, Consultants
Day 1
4th Annual Pharmaceutical PLM
Tuesday 14th September 2010
09:00 Registration and refreshments
09:30 Chair’s opening remarks
Senior Representative
Infosys
09:40 Towards an integrated PLM solution for pharmaceutical industry – A perspective
• PLM maturity model and pharma challenges
• Solution ideation, As Is landscape and business goals
• Case study and Infosys credentials
Amit Sharma
Head, PLM Europe, Infosys Product Lifecycle Engineering Services
Infosys
10:20 Lifecycle management begins at phase II
• Evaluating commercial probability of success in early-stage portfolios
• Evaluating strategic options in phase II
• Roadmapping product launch options
• What ‘great’ looks like: case studies of brands that managed early
Mike Rea
Chief Executive Officer
IdeaPharma
11:00 Morning refreshment & networking session
11:20 Developing differentiation, innovation, and long-term growth strategies with lifecycle technologies
• Brief introduction on fundamentals of oral controlled release
• Product innovation through mechanistic changes in product design
• Examining drug delivery technologies as growth driver
• Big pharma and generic company perspective
• Looming patent losses for big pharma
• Examining how emerging markets drive growth
Vishal K. Gupta
Director, Pharmaceutical R&D
Covidien
12:00 Maximising ROI through patent protection strategies
• Understanding how to effectively reassess, develop and exploit patent protection strategies
• Enhancing market exclusivity and revenue returns over the lifecycles
of new drugs
• Successful case scenarios on strategy application
Nigel Stoate
Partner
Taylor Wessing
12:40 Lunch
13:40 Enhancing life cycle management through effective pharmaceutical licensing strategies
• Examining the licensing process in pharmaceutical industry
• Developing effective strategies while managing costs effectively
Jonathan Deutsch
Director Pharma Development Safety, Licensing
and Early Development
Hoffmann-La Roche
14:20 Effective brand optimisation
• Development of intangible value
• Planning for PLM - when is early? And when is too late?
• Best practice methodologies
• Yo-yo marketing – the customer IS king
• Putting the ‘life’ in lifecycle
Paul FitzGerald
Owner
Syntropy Medica
15:00 Afternoon refreshments & networking session
15:20 Taking the pain out of the launch process
• Ensuring consistency of label/graphics design
• Examining best of breed approaches to product launches
• Removing complexity of PLM
Martin Hawkins
Executive Director
Sun Brand Technologies
16:00 Reformulation using new technologies as a strategy to lifecycle management
• Examples on how new technology and patent protection can maximise the value of a product.
• How the clinical benefit needs to be balanced to the clinical and regulatory requirements.
• The importance of a timely lifecycle management strategy
Peter G Nielsen
Executive Vice President of Pharmaceutical Development and Chemistry Manufacturing & Control
Lifecycle Pharma
16:40 Chair’s closing remarks
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 1
4th Annual Pharmaceutical PLM
Tuesday 15th September 2010
09:00 Registration and refreshments
09:30 Chair’s opening remarks
Marc Sluijs
EMEA Business Development Director Life Sciences
Oracle
09:40 Mergers and acquisitions: The need for PLM tools
• How does it affect the longer term delivery by the vendors to
the customers?
• Harmonising the product portfolio and enhancing visibility across
the value chain
• Managing portfolio of drug candidates – from research to
development and beyond
Alok Aggarwal
Co-Founder and Chairman
Evalueserve
10:20 Optimising life cycle management through
efficiency measurements
• Explaining why is there a need to measure
• Identifying appropriate efficiency measurement tools
• Defining the challenges
• Exploring some best practice examples
Alexandra C. Gruber
Director Business Development & Marketing
BIOCRATES Life Sciences
11:00 Morning refreshment & networking session
11:20 Panel Discussion: - The role of partnership in implementing PLM software
Panelists will identify and understand how partnerships with technology vendors can maximise value through an efficient PLM implementation.
EMEA Business Development Director Life Sciences
Oracle
12:00 Managing brands across the four phases of
product lifecycle
12:40 Lunch
13:40 Evaluating technical and integration issues in PLM
• Understanding the implementation process of PLM solutions
• Customisation and configuration issues within the pharmaceutical environment
• Configurable packages versus customised PLM projects
• Discuss successful PLM strategies
14:20 Presentation to be announced
Lorna Brazell
Partner
Bird & Bird
15:00 Afternoon refreshments & networking session
15:20 Strategic product portfolio life cycle management
• Complexity and performance of the Product life cycle process
• Key objectives of Product portfolio Life Cycle Management PLCM
• Model based PLCM
- Conceptual design and structure
- Operational concept, Managers user interface und demonstration of case studies
• Benefits
Matej Janovjak
CEO
InSysteA
16:00 Managing drug safety throughout product
lifecycle management
• Understanding the benefit-risk decision making by prescribers and patients
• Adaptative design for RMP/REMS based on their outcome
• Best practices for developing transparency with safety governance committees
Ralph C. Schimmer
Global Head Drug Safety Sciences - Metabolism and Cardiovascular
F.Hoffmann-La Roche
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=114680&rt=Conference-on-4th-Annual-Pharmaceutical-PLM.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
14th - 15th September 2010, BSG Conference Centre, London, UK
Key Speakers
• Jonathan Deutsch, Director Pharma Development Safety, Licensing and Early Development, Hoffmann-La Roche
• Maciej Gil, Medical & Regulatory Director & CIS, Eli Lilly Russia
• Mario Maio, Head of Formulation & Process Development , Merck Serono
• James Down, Vice President, Product Lifecycle Management, Beckton Dickinson
• Ralph C. Schimmer, Global Head Drug Safety Sciences - Metabolism and Cardiovascular, Hoffmann-La Roche
• Vishal K. Gupta, Director Pharmaceutical R&D, Covidien
• Alok Aggarwal, Co-Founder and Chairman, Evalueserve
• Alexandra C. Gruber, Director Business Development & Marketing, BIOCRATES Life Sciences
• Mike Rea, Chief Executive Officer, IdeaPharma
• Peter G Nielsen, Executive Vice President of Pharmaceutical Development and Chemistry Manufacturing & Control, Lifecycle Pharma
• Nigel Stoate, Partner, Taylor Wessing
• Paul FitzGerald, Owner, Syntropy Medica
Pharmaceutical and biopharmaceutical companies are under severe pressure to improve product pipelines, accelerate time to market, and improve margins on existing products, while maintaining strict adherence to quality principles and regulatory requirements. It is imperative that pharmaceutical and biotech companies address these business challenges to stay competitive, increase revenue, enhance profit, and reduce the risk of noncompliance.
4th Annual Pharmaceutical PLM Conference will feature keynote addresses, presentations, case studies and interactive discussions from development to commercialisation, quality control, supplier issues, regulation and inspection. Please be sure to register your participation amongst the industry's elite for this intensive two-day of learning, networking and exploiting business opportunities.
By attending this conference, you will:
• Hear from R&D, design, engineering and technical professionals and executives
• Recognise the potential benefit of PLM in drug development process
• Learn how to achieve target quality profiles and comply with regulatory requirements
• Find out how partnerships with technology vendors can maximise value through an efficient PLM implementation
• Eliminate inconsistent branding, improve brand communication and enable brand growth
• Gain knowledge of how to manage PLM in a patent environment
Who should attend:
Vice/Presidents, Directors, Heads of:-
• Lifecycle Management
• Portfolio Management Research & Development
• Strategic Planning Partnering
• Licensing & Alliance
• Process Chemists, Pre-Formulation
• Formulation Clinical Scientists
• Clinical Investigators
• Brand Management
• Patent
• Regulatory Affairs
Target audience - industry
Pharmaceutical companies, biopharmaceutical
companies, software vendors, PLM vendors, Analysts, Consultants
Day 1
4th Annual Pharmaceutical PLM
Tuesday 14th September 2010
09:00 Registration and refreshments
09:30 Chair’s opening remarks
Senior Representative
Infosys
09:40 Towards an integrated PLM solution for pharmaceutical industry – A perspective
• PLM maturity model and pharma challenges
• Solution ideation, As Is landscape and business goals
• Case study and Infosys credentials
Amit Sharma
Head, PLM Europe, Infosys Product Lifecycle Engineering Services
Infosys
10:20 Lifecycle management begins at phase II
• Evaluating commercial probability of success in early-stage portfolios
• Evaluating strategic options in phase II
• Roadmapping product launch options
• What ‘great’ looks like: case studies of brands that managed early
Mike Rea
Chief Executive Officer
IdeaPharma
11:00 Morning refreshment & networking session
11:20 Developing differentiation, innovation, and long-term growth strategies with lifecycle technologies
• Brief introduction on fundamentals of oral controlled release
• Product innovation through mechanistic changes in product design
• Examining drug delivery technologies as growth driver
• Big pharma and generic company perspective
• Looming patent losses for big pharma
• Examining how emerging markets drive growth
Vishal K. Gupta
Director, Pharmaceutical R&D
Covidien
12:00 Maximising ROI through patent protection strategies
• Understanding how to effectively reassess, develop and exploit patent protection strategies
• Enhancing market exclusivity and revenue returns over the lifecycles
of new drugs
• Successful case scenarios on strategy application
Nigel Stoate
Partner
Taylor Wessing
12:40 Lunch
13:40 Enhancing life cycle management through effective pharmaceutical licensing strategies
• Examining the licensing process in pharmaceutical industry
• Developing effective strategies while managing costs effectively
Jonathan Deutsch
Director Pharma Development Safety, Licensing
and Early Development
Hoffmann-La Roche
14:20 Effective brand optimisation
• Development of intangible value
• Planning for PLM - when is early? And when is too late?
• Best practice methodologies
• Yo-yo marketing – the customer IS king
• Putting the ‘life’ in lifecycle
Paul FitzGerald
Owner
Syntropy Medica
15:00 Afternoon refreshments & networking session
15:20 Taking the pain out of the launch process
• Ensuring consistency of label/graphics design
• Examining best of breed approaches to product launches
• Removing complexity of PLM
Martin Hawkins
Executive Director
Sun Brand Technologies
16:00 Reformulation using new technologies as a strategy to lifecycle management
• Examples on how new technology and patent protection can maximise the value of a product.
• How the clinical benefit needs to be balanced to the clinical and regulatory requirements.
• The importance of a timely lifecycle management strategy
Peter G Nielsen
Executive Vice President of Pharmaceutical Development and Chemistry Manufacturing & Control
Lifecycle Pharma
16:40 Chair’s closing remarks
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 1
4th Annual Pharmaceutical PLM
Tuesday 15th September 2010
09:00 Registration and refreshments
09:30 Chair’s opening remarks
Marc Sluijs
EMEA Business Development Director Life Sciences
Oracle
09:40 Mergers and acquisitions: The need for PLM tools
• How does it affect the longer term delivery by the vendors to
the customers?
• Harmonising the product portfolio and enhancing visibility across
the value chain
• Managing portfolio of drug candidates – from research to
development and beyond
Alok Aggarwal
Co-Founder and Chairman
Evalueserve
10:20 Optimising life cycle management through
efficiency measurements
• Explaining why is there a need to measure
• Identifying appropriate efficiency measurement tools
• Defining the challenges
• Exploring some best practice examples
Alexandra C. Gruber
Director Business Development & Marketing
BIOCRATES Life Sciences
11:00 Morning refreshment & networking session
11:20 Panel Discussion: - The role of partnership in implementing PLM software
Panelists will identify and understand how partnerships with technology vendors can maximise value through an efficient PLM implementation.
EMEA Business Development Director Life Sciences
Oracle
12:00 Managing brands across the four phases of
product lifecycle
12:40 Lunch
13:40 Evaluating technical and integration issues in PLM
• Understanding the implementation process of PLM solutions
• Customisation and configuration issues within the pharmaceutical environment
• Configurable packages versus customised PLM projects
• Discuss successful PLM strategies
14:20 Presentation to be announced
Lorna Brazell
Partner
Bird & Bird
15:00 Afternoon refreshments & networking session
15:20 Strategic product portfolio life cycle management
• Complexity and performance of the Product life cycle process
• Key objectives of Product portfolio Life Cycle Management PLCM
• Model based PLCM
- Conceptual design and structure
- Operational concept, Managers user interface und demonstration of case studies
• Benefits
Matej Janovjak
CEO
InSysteA
16:00 Managing drug safety throughout product
lifecycle management
• Understanding the benefit-risk decision making by prescribers and patients
• Adaptative design for RMP/REMS based on their outcome
• Best practices for developing transparency with safety governance committees
Ralph C. Schimmer
Global Head Drug Safety Sciences - Metabolism and Cardiovascular
F.Hoffmann-La Roche
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=114680&rt=Conference-on-4th-Annual-Pharmaceutical-PLM.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Vaccine Research & Innovation 2010
Key Speakers
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Subscribe to:
Posts (Atom)